Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Mears sees FY profit 'modestly' ahead of market views

(Sharecast News) - Mears posted a rise in interim pre-tax profit on Thursday despite a dip in revenues and said full-year profit was set to be "modestly" ahead of market expectations. In the six months to 30 June, adjusted pre-tax profit rose 5% to £32m.

Revenues ticked down 4% from the same period a year earlier to £559.4m, with some normalisation in the group's management-led activities, partially offset by 8% revenue growth in maintenance-led activities.

Management-led activities reduced by 14% due to the continued normalisation of revenues relating to the Asylum Accommodation and Support Contract, Mears said. The other management-led activities delivered "modest" growth, mainly from a short-term contract to support the Afghan Relocation and Assistance Policy, delivered for the Ministry of Defence.

The interim dividend was lifted 18% to 5.60p a share.

Chief executive Lucas Critchley said: "I am delighted to report a period of strong operational, financial and strategic performance. We have continued to make progress against each of our key strategic goals; delivering growth in maintenance activities, developing a full compliance and asset management offer, and positioning the group to deliver additional housing services to Central Government.

"Importantly, we have continued to do the basics well, which underpins our drive for both service excellence and strengthening commercial performance."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.